Humana Inc. (NYSE:HUM) is Pzena Investment Management LLC's 9th Largest Position

Pzena Investment Management LLC raised its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 44.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,609,382 shares of the insurance provider's stock after purchasing an additional 1,103,132 shares during the quarter. Humana accounts for approximately 3.2% of Pzena Investment Management LLC's investment portfolio, making the stock its 9th largest holding. Pzena Investment Management LLC owned approximately 3.00% of Humana worth $915,736,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in HUM. FPC Investment Advisory Inc. bought a new stake in shares of Humana during the fourth quarter worth $27,000. Centricity Wealth Management LLC purchased a new position in shares of Humana during the fourth quarter valued at $30,000. Ashton Thomas Securities LLC purchased a new position in shares of Humana during the third quarter valued at $31,000. OFI Invest Asset Management purchased a new position in shares of Humana during the fourth quarter valued at $33,000. Finally, Atwood & Palmer Inc. increased its stake in shares of Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after buying an additional 60 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company's stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.32% of the stock is currently owned by corporate insiders.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. StockNews.com lowered Humana from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Barclays lifted their target price on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research note on Thursday, February 13th. Truist Financial lifted their target price on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research note on Monday, January 6th. Finally, JPMorgan Chase & Co. cut their target price on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Twenty equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $285.68.

Humana Stock Performance

Shares of Humana stock traded down $1.04 on Tuesday, reaching $250.21. 1,387,813 shares of the stock were exchanged, compared to its average volume of 1,676,635. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The firm has a market capitalization of $30.19 billion, a price-to-earnings ratio of 25.15, a PEG ratio of 2.05 and a beta of 0.57. The business has a 50 day moving average price of $271.67 and a two-hundred day moving average price of $281.65.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.41%. The ex-dividend date of this dividend is Friday, March 28th. Humana's payout ratio is presently 35.58%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.